Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib.

PubWeight™: 1.13‹?› | Rank: Top 10%

🔗 View Article (PMC 3134264)

Published in Chem Biol on May 27, 2011

Authors

Anne C Mirabella1, Alexandre A Pletnev, Sondra L Downey, Bogdan I Florea, Tamer B Shabaneh, Matthew Britton, Martijn Verdoes, Dmitri V Filippov, Herman S Overkleeft, Alexei F Kisselev

Author Affiliations

1: Department of Pharmacology and Toxicology, Dartmouth Medical School, Dartmouth College, Lebanon, NH 03756, USA.

Articles citing this

Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol (2012) 2.26

Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases. Expert Rev Mol Med (2011) 1.12

Validation of the proteasome as a therapeutic target in Plasmodium using an epoxyketone inhibitor with parasite-specific toxicity. Chem Biol (2012) 1.09

DangER: protein ovERload. Targeting protein degradation to treat myeloma. Haematologica (2012) 1.06

Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites. J Med Chem (2013) 0.92

Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib. PLoS One (2013) 0.91

Assessing subunit dependency of the Plasmodium proteasome using small molecule inhibitors and active site probes. ACS Chem Biol (2014) 0.90

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance. Blood Cancer J (2013) 0.89

Discovery of a potent and highly β1 specific proteasome inhibitor from a focused library of urea-containing peptide vinyl sulfones and peptide epoxyketones. Org Biomol Chem (2011) 0.81

Subunit specific inhibitors of proteasomes and their potential for immunomodulation. Curr Opin Chem Biol (2014) 0.80

A FRET-based approach for identification of proteasome catalytic subunit composition. Mol Biosyst (2014) 0.79

Activity-based imaging probes of the proteasome. Cell Biochem Biophys (2013) 0.79

Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients. Br J Haematol (2016) 0.78

Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay. Br J Haematol (2016) 0.78

Proteasome as a Molecular Target of Microcystin-LR. Toxins (Basel) (2015) 0.75

Elucidating the catalytic subunit composition of distinct proteasome subtypes: a crosslinking approach employing bifunctional activity-based probes. Chembiochem (2014) 0.75

Multicolor monitoring of the proteasome's catalytic signature. ACS Chem Biol (2014) 0.75

The future of proteasome inhibitors in relapsed/refractory multiple myeloma. Oncology (Williston Park) (2011) 0.75

Flumazenil decreases surface expression of α4β2δ GABAA receptors by increasing the rate of receptor internalization. Brain Res Bull (2015) 0.75

Validation of the 2nd Generation Proteasome Inhibitor Oprozomib for Local Therapy of Pulmonary Fibrosis. PLoS One (2015) 0.75

Inhibition of the Proteasome β2 Site Sensitizes Triple-Negative Breast Cancer Cells to β5 Inhibitors and Suppresses Nrf1 Activation. Cell Chem Biol (2017) 0.75

Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). Haematologica (2015) 0.75

The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells. Cancer Chemother Pharmacol (2015) 0.75

Articles cited by this

MHC ligands and peptide motifs: first listing. Immunogenetics (1995) 7.78

Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci U S A (1999) 5.28

Proteasome inhibitors: from research tools to drug candidates. Chem Biol (2001) 5.06

The development of proteasome inhibitors as anticancer drugs. Cancer Cell (2004) 4.46

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res (2007) 3.85

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell (2005) 3.41

Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem (2006) 2.59

Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates. Methods Enzymol (2005) 2.49

Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res (2010) 2.27

Cathepsin D--many functions of one aspartic protease. Crit Rev Oncol Hematol (2008) 2.26

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res (2009) 2.17

Protein degradation and the generation of MHC class I-presented peptides. Adv Immunol (2002) 2.17

26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide. EMBO J (2001) 2.09

Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods (2005) 1.78

Global analysis of proteasomal substrate specificity using positional-scanning libraries of covalent inhibitors. Proc Natl Acad Sci U S A (2001) 1.58

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood (2007) 1.54

A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo. Chem Biol (2006) 1.54

Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic beta-subunits. Chem Biol (2001) 1.52

Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem (2009) 1.50

Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol (2005) 1.50

Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites. Chem Biol (2009) 1.47

Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res (2005) 1.39

Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach. Biochim Biophys Acta (2004) 1.36

Chemistry in living cells: detection of active proteasomes by a two-step labeling strategy. Angew Chem Int Ed Engl (2003) 1.25

Substrate specificity of the human proteasome. Chem Biol (2001) 1.19

Cell-based bioluminescent assays for all three proteasome activities in a homogeneous format. Anal Biochem (2009) 1.06

Activity-based profiling reveals reactivity of the murine thymoproteasome-specific subunit beta5t. Chem Biol (2010) 1.01

Probing structural determinants distal to the site of hydrolysis that control substrate specificity of the 20S proteasome. Chem Biol (2002) 1.01

Cathepsin S and related lysosomal endopeptidases. Methods Enzymol (1994) 1.00

Bifunctional inhibitors of the trypsin-like activity of eukaryotic proteasomes. Chem Biol (1999) 0.97

Kinetic studies of the branched chain amino acid preferring peptidase activity of the 20S proteasome: development of a continuous assay and inhibition by tripeptide aldehydes and clasto-lactacystin beta-lactone. Biochemistry (1998) 0.95

Nature of pharmacophore influences active site specificity of proteasome inhibitors. J Biol Chem (2010) 0.94

Joining the army of proteasome inhibitors. Chem Biol (2008) 0.92

Azido-BODIPY acid reveals quantitative Staudinger-Bertozzi ligation in two-step activity-based proteasome profiling. Chembiochem (2008) 0.90

Incorporation of fluorinated phenylalanine generates highly specific inhibitor of proteasome's chymotrypsin-like sites. J Med Chem (2010) 0.85

Peptidyl vinyl ester derivatives: new class of selective inhibitors of proteasome trypsin-like activity. J Med Chem (2005) 0.84

Articles by these authors

A role for Piwi and piRNAs in germ cell maintenance and transposon silencing in Zebrafish. Cell (2007) 6.31

The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage. Cell (2003) 4.97

Certain pairs of ubiquitin-conjugating enzymes (E2s) and ubiquitin-protein ligases (E3s) synthesize nondegradable forked ubiquitin chains containing all possible isopeptide linkages. J Biol Chem (2007) 3.68

Dynamic assembly of end-joining complexes requires interaction between Ku70/80 and XRCC4. Proc Natl Acad Sci U S A (2006) 2.71

Asymmetric proteasome segregation as a mechanism for unequal partitioning of the transcription factor T-bet during T lymphocyte division. Immunity (2011) 2.34

Quantitative phosphoproteomics identifies substrates and functional modules of Aurora and Polo-like kinase activities in mitotic cells. Sci Signal (2011) 2.33

Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol (2012) 2.26

Highly efficient ruthenium catalysts for the formation of tetrasubstituted olefins via ring-closing metathesis. Org Lett (2007) 2.02

CSA-dependent degradation of CSB by the ubiquitin-proteasome pathway establishes a link between complementation factors of the Cockayne syndrome. Genes Dev (2006) 1.79

Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods (2005) 1.78

Analysis of protease activity in live antigen-presenting cells shows regulation of the phagosomal proteolytic contents during dendritic cell activation. J Exp Med (2002) 1.64

Thioglycosides in sequential glycosylation strategies. Chem Soc Rev (2005) 1.60

A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo. Chem Biol (2006) 1.54

Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA. J Biol Chem (2011) 1.49

Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites. Chem Biol (2009) 1.47

The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites. J Biol Chem (2003) 1.46

Synthesis of pH-activatable red fluorescent BODIPY dyes with distinct functionalities. Org Lett (2011) 1.44

Ph2SO/Tf2O: a powerful promotor system in chemoselective glycosylations using thioglycosides. Org Lett (2003) 1.42

Glycosphingolipids--nature, function, and pharmacological modulation. Angew Chem Int Ed Engl (2009) 1.41

Functional imaging of proteases: recent advances in the design and application of substrate-based and activity-based probes. Curr Opin Chem Biol (2011) 1.31

Development of adamantan-1-yl-methoxy-functionalized 1-deoxynojirimycin derivatives as selective inhibitors of glucosylceramide metabolism in man. J Org Chem (2007) 1.28

Muscle wasting in aged, sarcopenic rats is associated with enhanced activity of the ubiquitin proteasome pathway. J Biol Chem (2010) 1.28

Ultrasensitive in situ visualization of active glucocerebrosidase molecules. Nat Chem Biol (2010) 1.26

Chemistry in living cells: detection of active proteasomes by a two-step labeling strategy. Angew Chem Int Ed Engl (2003) 1.25

Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity. Proc Natl Acad Sci U S A (2009) 1.24

Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J Biol Chem (2007) 1.23

Crystal structure of HslUV complexed with a vinyl sulfone inhibitor: corroboration of a proposed mechanism of allosteric activation of HslV by HslU. J Mol Biol (2002) 1.21

A modular strategy toward the synthesis of heparin-like oligosaccharides using monomeric building blocks in a sequential glycosylation strategy. J Am Chem Soc (2005) 1.17

The conformation of neurotensin bound to its G protein-coupled receptor. Proc Natl Acad Sci U S A (2003) 1.14

Corrected structure of mirin, a small-molecule inhibitor of the Mre11-Rad50-Nbs1 complex. Nat Chem Biol (2009) 1.13

Structure and reactivity of an asymmetric complex between HslV and I-domain deleted HslU, a prokaryotic homolog of the eukaryotic proteasome. J Mol Biol (2003) 1.13

A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway. Oncogene (2004) 1.12

Thioglycuronides: synthesis and application in the assembly of acidic oligosaccharides. Org Lett (2004) 1.11

Nicotinamide riboside and nicotinic acid riboside salvage in fungi and mammals. Quantitative basis for Urh1 and purine nucleoside phosphorylase function in NAD+ metabolism. J Biol Chem (2008) 1.11

New approaches for dissecting protease functions to improve probe development and drug discovery. Nat Struct Mol Biol (2012) 1.11

Validation of the proteasome as a therapeutic target in Plasmodium using an epoxyketone inhibitor with parasite-specific toxicity. Chem Biol (2012) 1.09

An RNA virus hijacks an incognito function of a DNA repair enzyme. Proc Natl Acad Sci U S A (2012) 1.08

Bioorthogonal organic chemistry in living cells: novel strategies for labeling biomolecules. Org Biomol Chem (2004) 1.08

Mixing of peptides and electrophilic traps gives rise to potent, broad-spectrum proteasome inhibitors. Org Biomol Chem (2007) 1.07

Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies. J Inherit Metab Dis (2011) 1.07

Small-molecule inhibitors and probes for ubiquitin- and ubiquitin-like-specific proteases. Chembiochem (2005) 1.07

Functional imaging of legumain in cancer using a new quenched activity-based probe. J Am Chem Soc (2012) 1.05

The use of cyclic bifunctional protecting groups in oligosaccharide synthesis--an overview. Carbohydr Res (2006) 1.04

The Ku80 carboxy terminus stimulates joining and artemis-mediated processing of DNA ends. Mol Cell Biol (2008) 1.03

Automated solid-phase synthesis of β-mannuronic acid alginates. Angew Chem Int Ed Engl (2012) 1.02

Activity-based profiling reveals reactivity of the murine thymoproteasome-specific subunit beta5t. Chem Biol (2010) 1.01

Proteasome activity profiling: a simple, robust and versatile method revealing subunit-selective inhibitors and cytoplasmic, defense-induced proteasome activities. Plant J (2009) 1.01

Development of an activity-based probe and in silico design reveal highly selective inhibitors for diacylglycerol lipase-α in brain. Angew Chem Int Ed Engl (2013) 1.01

Functional proteomics of the active cysteine protease content in Drosophila S2 cells. Mol Cell Proteomics (2003) 1.01

Subclassification and biochemical analysis of plant papain-like cysteine proteases displays subfamily-specific characteristics. Plant Physiol (2012) 0.99

Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometry. Clin Chem (2012) 0.98

Accumulation of ubiquitin conjugates in a polyglutamine disease model occurs without global ubiquitin/proteasome system impairment. Proc Natl Acad Sci U S A (2009) 0.98

Stereodirecting effect of the pyranosyl C-5 substituent in glycosylation reactions. J Org Chem (2009) 0.97

Syringolin A selectively labels the 20 S proteasome in murine EL4 and wild-type and bortezomib-adapted leukaemic cell lines. Chembiochem (2009) 0.97

Non-invasive imaging of cysteine cathepsin activity in solid tumors using a 64Cu-labeled activity-based probe. PLoS One (2011) 0.97

An optimized activity-based probe for the study of caspase-6 activation. Chem Biol (2012) 0.97

The impact of oxacarbenium ion conformers on the stereochemical outcome of glycosylations. Carbohydr Res (2010) 0.96

A cell-permeable inhibitor and activity-based probe for the caspase-like activity of the proteasome. Bioorg Med Chem Lett (2007) 0.96

Relative quantification of proteasome activity by activity-based protein profiling and LC-MS/MS. Nat Protoc (2013) 0.96

TINS, target immobilized NMR screening: an efficient and sensitive method for ligand discovery. Chem Biol (2005) 0.95

TLR ligand-peptide conjugate vaccines: toward clinical application. Adv Immunol (2012) 0.95

Sequential one-pot glycosylations using 1-hydroxyl and 1-thiodonors. Org Lett (2003) 0.94

Human B lymphoblastoid cells contain distinct patterns of cathepsin activity in endocytic compartments and regulate MHC class II transport in a cathepsin S-independent manner. J Leukoc Biol (2004) 0.94

Nature of pharmacophore influences active site specificity of proteasome inhibitors. J Biol Chem (2010) 0.94

Acetylene functionalized BODIPY dyes and their application in the synthesis of activity based proteasome probes. Bioorg Med Chem Lett (2007) 0.94

LPS-induced formation of immunoproteasomes: TNF-α and nitric oxide production are regulated by altered composition of proteasome-active sites. Cell Biochem Biophys (2011) 0.94

Conjugation of nucleosides and oligonucleotides by [3+2] cycloaddition. J Org Chem (2007) 0.93

Automated solid-phase synthesis of hyaluronan oligosaccharides. Org Lett (2012) 0.93

Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites. J Med Chem (2013) 0.92

Novel activity-based probes for broad-spectrum profiling of retaining β-exoglucosidases in situ and in vivo. Angew Chem Int Ed Engl (2012) 0.92

Bioorthogonal chemistry: applications in activity-based protein profiling. Acc Chem Res (2011) 0.91

Minitags for small molecules: detecting targets of reactive small molecules in living plant tissues using 'click chemistry'. Plant J (2008) 0.91